Garry Nolan - 10 Nov 2022 Form 4 Insider Report for Akoya Biosciences, Inc. (AKYA)

Role
Director
Signature
/s/ Garry Nolan, by Brian McKelligon, as Attorney-in-Fact
Issuer symbol
AKYA
Transactions as of
10 Nov 2022
Transactions value $
-$324,529
Form type
4
Filing time
14 Nov 2022, 17:43:52 UTC
Previous filing
16 Sep 2022
Next filing
17 Nov 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKYA Common Stock Sale -$50,705 -3,810 -0.61% $13.31 618,978 10 Nov 2022 Direct F1
transaction AKYA Common Stock Sale -$265,858 -20,000 -3.2% $13.29 598,978 11 Nov 2022 Direct F2
transaction AKYA Common Stock Sale -$7,966 -600 -0.1% $13.28 598,378 14 Nov 2022 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.48, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.46, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.25 to $13.30, inclusive. The reporting person undertakes to provide to Akoya Biosciences, Inc., any security holder of Akoya Biosciences, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.